Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
Kaleido Biosciences股價暴跌至52周低點，閲讀原因
- Kaleido Biosciences Inc (NASDAQ:KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations.
- The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting effective by April 28.
- The Board of Directors voted to immediately wind down and cease all of the Company's ongoing operations.
- Related: Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target.
- In connection with the cessation of activities, the employment of all of the Company's remaining employees was terminated effective immediately.
- As previously announced, the Company had initiated a strategic process, but it did not result in the identification of any viable transactions, given its limited remaining resources.
- The Company cannot continue operations and believes that the best alternative is an orderly wind-down process.
- Price Action: KLDO shares are down 74.9% at $0.37 during the market session on the last check Friday.
- 卡萊多生物科學公司納斯達克股票代碼：KLDO)已發出正式通知，自願將其普通股從納斯達克退市，因為公司將停止所有業務。
- 該公司預計將於4月18日前向美國證券交易委員會提交一份25號表格，以使4月28日生效的自願退市生效。
- 董事會投票決定立即結束並停止該公司所有正在進行的業務。
- 相關： Kaleido暫停即將進行的COPD第二階段試驗，Piper Sandler下調目標價格.
- 關於活動的停止，公司所有剩餘員工的僱傭被立即終止。
- 正如先前宣佈的那樣，該公司已經啟動了一項戰略進程，但由於其剩餘資源有限，因此沒有確定任何可行的交易。
- 該公司無法繼續運營，並認為最好的替代方案是有序的清盤過程。
- 價格行動：KLDO股價週五尾盤下跌74.9%，至0.37美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。